Allogene Therapeutics, Inc. (ALLO)

2.02USD -3.35% (-0.07)

Over 6M: -23.8%

Style
Area Line Line with markers Steps Candles Hollow candles Bars

Candles and bars need the day’s open, high and low, and need room to be drawn in: past about a year of trading a body is thinner than a hairline, so those three offer the longest window that fits instead.

2 2.5 3
Mar Apr May Jun Jul Aug

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '23 — Operating Income: -63M Q3 '23 — Operating Cash Flow: -55.5M Q3 '23 — Free Cash Flow: -55.5M Q4 '23 — Operating Income: -85.1M Q4 '23 — Operating Cash Flow: -53.7M Q4 '23 — Free Cash Flow: -53.9M Q1 '24 — Operating Income: -69.5M Q1 '24 — Operating Cash Flow: -55.9M Q1 '24 — Free Cash Flow: -55.9M Q2 '24 — Operating Income: -71.4M Q2 '24 — Operating Cash Flow: -63.6M Q2 '24 — Free Cash Flow: -63.6M Q3 '24 — Operating Income: -71.8M Q3 '24 — Operating Cash Flow: -44.1M Q3 '24 — Free Cash Flow: -44.5M Q4 '24 — Operating Income: -60.5M Q4 '24 — Operating Cash Flow: -36.7M Q4 '24 — Free Cash Flow: -37M Q1 '25 — Operating Income: -65.2M Q1 '25 — Operating Cash Flow: -52.9M Q1 '25 — Free Cash Flow: -53M Q2 '25 — Operating Income: -56.8M Q2 '25 — Operating Cash Flow: -39M Q2 '25 — Free Cash Flow: -39.1M Q3 '25 — Operating Income: -44.9M Q3 '25 — Operating Cash Flow: -29.7M Q3 '25 — Free Cash Flow: -29.9M Q4 '25 — Operating Income: -42.4M Q4 '25 — Operating Cash Flow: -27.6M Q4 '25 — Free Cash Flow: -27.6M Q1 '26 — Operating Income: -46.1M Q1 '26 — Operating Cash Flow: -12.9M Q1 '26 — Free Cash Flow: -12.9M Q2 '26 — Operating Income: -46.9M Q2 '26 — Operating Cash Flow: -32M Q2 '26 — Free Cash Flow: -32.1M -80M -60M -40M -20M 0
Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26
Operating Income Operating Cash Flow Free Cash Flow

Figures as at 2025-12-31, reported in USD. The newest fact in the filings is dated 2026-06-30, 62 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.5
ROIC -137.5%
Accruals -11.5%
ROA -30.1%
ROCE -34.8%
ROE -37.9%
Asset turnover —
Capex / sales —
EBITDA margin —
FCF margin —
Gross margin —
OCF / EBIT —
OCF margin —
OE margin —
Oper. margin —
Profit margin —
SBC / sales —

1 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
EV/OE -2.5×
P/C 2.1×
P/B 1.6×
FCF yield -15.0%
Div. yield —
EV/EBIT —
EV/GP —
EV/Sales —
Fwd P/E —
P/E —
PEG —

1 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

1.0
RPO / sales —
RPO growth —
Segment HHI —

2 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

6.8
Current ratio 10.7×
ND/EBITDA 0.95
Interest cover -138.7×
Debt / Eq 0.0×
Debt payback 0.0 yr
Quick ratio 10.7×
Cash runway 3.2 yr
F-score 2.6 pts
Cash / Debt —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

1.0
Sales CAGR 4Y -100.0%
Sales/sh Y/Y -100.0%
Shares change +13.3%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —
Sales Q/Q —

2 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.